Zhejiang Hisoar Pharmaceutical Co Ltd
Zhejiang Hisoar Pharmaceutical Co., Ltd. engages in the manufacture of pharmaceutical products and dyes in China and internationally. The company offers antibiotics, cardiovascular, hypoglycemic, fine chemicals, formulations, intermediates, and other products. It also provides dyestuff, and intermediates of dyestuff and pigment; and manufactures environmental protection related equipment, medical… Read more
Zhejiang Hisoar Pharmaceutical Co Ltd (002099) - Net Assets
Latest net assets as of September 2025: CN¥5.11 Billion CNY
Based on the latest financial reports, Zhejiang Hisoar Pharmaceutical Co Ltd (002099) has net assets worth CN¥5.11 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.28 Billion) and total liabilities (CN¥2.17 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.11 Billion |
| % of Total Assets | 70.23% |
| Annual Growth Rate | 21.56% |
| 5-Year Change | -12.31% |
| 10-Year Change | 43.64% |
| Growth Volatility | 91.31 |
Zhejiang Hisoar Pharmaceutical Co Ltd - Net Assets Trend (2003–2024)
This chart illustrates how Zhejiang Hisoar Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Hisoar Pharmaceutical Co Ltd (2003–2024)
The table below shows the annual net assets of Zhejiang Hisoar Pharmaceutical Co Ltd from 2003 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.13 Billion | -8.39% |
| 2023-12-31 | CN¥5.60 Billion | -8.24% |
| 2022-12-31 | CN¥6.10 Billion | -0.14% |
| 2021-12-31 | CN¥6.11 Billion | +4.47% |
| 2020-12-31 | CN¥5.85 Billion | +2.23% |
| 2019-12-31 | CN¥5.72 Billion | +6.19% |
| 2018-12-31 | CN¥5.39 Billion | +4.83% |
| 2017-12-31 | CN¥5.14 Billion | +7.79% |
| 2016-12-31 | CN¥4.77 Billion | +33.52% |
| 2015-12-31 | CN¥3.57 Billion | +12.40% |
| 2014-12-31 | CN¥3.18 Billion | +402.33% |
| 2013-12-31 | CN¥632.80 Million | -14.26% |
| 2012-12-31 | CN¥738.05 Million | +0.15% |
| 2011-12-31 | CN¥736.96 Million | +15.50% |
| 2010-12-31 | CN¥638.04 Million | +13.57% |
| 2009-12-31 | CN¥561.79 Million | +2.61% |
| 2008-12-31 | CN¥547.50 Million | +1.75% |
| 2007-12-31 | CN¥538.06 Million | +3.62% |
| 2006-12-31 | CN¥519.27 Million | +183.82% |
| 2005-12-31 | CN¥182.96 Million | +38.58% |
| 2004-12-31 | CN¥132.03 Million | +55.28% |
| 2003-12-31 | CN¥85.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Hisoar Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1117.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥475.21 Million | 9.25% |
| Common Stock | CN¥1.62 Billion | 31.50% |
| Other Comprehensive Income | CN¥305.02 Million | 5.94% |
| Other Components | CN¥2.74 Billion | 53.32% |
| Total Equity | CN¥5.14 Billion | 100.00% |
Zhejiang Hisoar Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Hisoar Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MFA FINANCIAL NEW DL -01
F:M4ZA
|
$881.93 Million |
|
Suzhou Veichi Electric Co. Ltd. A
SHG:688698
|
$881.96 Million |
|
Transcontinental Inc
PINK:TCLAF
|
$882.19 Million |
|
Samhällsbyggnadsbolaget i Norden AB (publ)
F:JSIA
|
$882.23 Million |
|
Beijing Shunxin Agriculture Co Ltd
SHE:000860
|
$880.58 Million |
|
Zhejiang Yonghe Refrigerant Co Ltd
SHG:605020
|
$880.48 Million |
|
Guangdong Macro Co Ltd
SHE:000533
|
$880.32 Million |
|
Cementir Holding
LSE:0HY2
|
$880.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Hisoar Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,606,352,298 to 5,139,071,751, a change of -467,280,547 (-8.3%).
- Net loss of 330,267,195 reduced equity.
- Dividend payments of 28,062,295 reduced retained earnings.
- Share repurchases of 151,419,651 reduced equity.
- Other comprehensive income increased equity by 25,432,086.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-330.27 Million | -6.43% |
| Dividends Paid | CN¥28.06 Million | -0.55% |
| Share Repurchases | CN¥151.42 Million | -2.95% |
| Other Comprehensive Income | CN¥25.43 Million | +0.49% |
| Other Changes | CN¥17.04 Million | +0.33% |
| Total Change | CN¥- | -8.33% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Hisoar Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.18x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 42.59x to 2.18x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | CN¥0.17 | CN¥7.13 | x |
| 2004-12-31 | CN¥0.26 | CN¥7.13 | x |
| 2005-12-31 | CN¥0.37 | CN¥7.13 | x |
| 2006-12-31 | CN¥1.07 | CN¥7.13 | x |
| 2007-12-31 | CN¥0.82 | CN¥7.13 | x |
| 2008-12-31 | CN¥0.85 | CN¥7.13 | x |
| 2009-12-31 | CN¥0.88 | CN¥7.13 | x |
| 2010-12-31 | CN¥0.98 | CN¥7.13 | x |
| 2011-12-31 | CN¥1.14 | CN¥7.13 | x |
| 2012-12-31 | CN¥1.09 | CN¥7.13 | x |
| 2013-12-31 | CN¥0.95 | CN¥7.13 | x |
| 2014-12-31 | CN¥2.18 | CN¥7.13 | x |
| 2015-12-31 | CN¥2.50 | CN¥7.13 | x |
| 2016-12-31 | CN¥3.18 | CN¥7.13 | x |
| 2017-12-31 | CN¥3.16 | CN¥7.13 | x |
| 2018-12-31 | CN¥3.39 | CN¥7.13 | x |
| 2019-12-31 | CN¥3.56 | CN¥7.13 | x |
| 2020-12-31 | CN¥3.62 | CN¥7.13 | x |
| 2021-12-31 | CN¥3.78 | CN¥7.13 | x |
| 2022-12-31 | CN¥3.77 | CN¥7.13 | x |
| 2023-12-31 | CN¥3.47 | CN¥7.13 | x |
| 2024-12-31 | CN¥3.27 | CN¥7.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Hisoar Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.04%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.45x
- Recent ROE (-6.43%) is below the historical average (7.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 27.37% | 6.00% | 1.03x | 4.42x | CN¥14.23 Million |
| 2004 | 27.29% | 6.94% | 1.31x | 3.01x | CN¥22.26 Million |
| 2005 | 27.39% | 7.18% | 1.20x | 3.19x | CN¥31.49 Million |
| 2006 | 9.86% | 6.61% | 0.84x | 1.78x | CN¥-728.86K |
| 2007 | 5.80% | 3.00% | 1.09x | 1.77x | CN¥-22.46 Million |
| 2008 | 4.70% | 2.41% | 1.05x | 1.86x | CN¥-28.87 Million |
| 2009 | 5.42% | 3.39% | 0.90x | 1.78x | CN¥-25.59 Million |
| 2010 | 13.49% | 7.97% | 0.94x | 1.80x | CN¥22.14 Million |
| 2011 | 14.42% | 8.09% | 0.90x | 1.97x | CN¥32.18 Million |
| 2012 | 3.20% | 1.99% | 0.60x | 2.69x | CN¥-48.39 Million |
| 2013 | -13.18% | -7.07% | 0.55x | 3.39x | CN¥-144.42 Million |
| 2014 | 1.68% | 4.06% | 0.32x | 1.31x | CN¥-264.92 Million |
| 2015 | 14.41% | 20.96% | 0.51x | 1.35x | CN¥158.03 Million |
| 2016 | 4.72% | 9.25% | 0.35x | 1.45x | CN¥-251.75 Million |
| 2017 | 6.66% | 14.82% | 0.31x | 1.45x | CN¥-171.98 Million |
| 2018 | 11.22% | 22.25% | 0.39x | 1.31x | CN¥65.95 Million |
| 2019 | 13.46% | 26.20% | 0.44x | 1.18x | CN¥198.34 Million |
| 2020 | 5.46% | 12.94% | 0.34x | 1.23x | CN¥-265.49 Million |
| 2021 | 1.56% | 3.83% | 0.31x | 1.31x | CN¥-516.27 Million |
| 2022 | 1.44% | 3.25% | 0.32x | 1.37x | CN¥-522.78 Million |
| 2023 | -7.49% | -19.34% | 0.29x | 1.34x | CN¥-980.69 Million |
| 2024 | -6.43% | -17.04% | 0.26x | 1.45x | CN¥-844.17 Million |
Industry Comparison
This section compares Zhejiang Hisoar Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Hisoar Pharmaceutical Co Ltd (002099) | CN¥5.11 Billion | 27.37% | 0.42x | $880.90 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |